Akeso climbs after China regulator nod for new lung cancer drug application
13/08/2026 04:38
BUZZ-Akeso climbs after China regulator nod for new lung cancer drug application ** Shares of China-based drug developer Akeso Inc 9926.HK climb 3.5% to HK$105.7, on track for the biggest one-day pct gain since August 7
** Stock on course for eighth consecutive session of gains
** Akeso says China's National Medical Products Administration (NMPA) approves New Drug Application for its bi-specific immunotherapy drug Ivonescimab for first-line treatment of advanced squamous non-small cell lung cancer
** It marks Ivonescimab's third major approval - co
** YTD, stock down 6.6%, while Hang Seng Biotech Index .HSBIO up 10.7%
(Reporting by Donny Kwok)
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals